Evonik Invests $108M in Vancouver GMP Lipid Drug-Product Facility
- Evonik is building a new GMP drug-product manufacturing facility in Vancouver with over three times the capacity of its current site, targeting lipid-based therapeutics.
- The $150 million CAD investment ($108 million USD) is supported by $49 million CAD in Canadian federal government funding; production begins end of 2029.
- The facility will expand quality control and microbiological testing capabilities to accelerate product release for clinical and commercial use.
Operational Impact
Evonik's Vancouver facility adds significant North American lipid drug-product capacity for biotech and pharma customers, with production commencing end of 2029 and enhanced QC/microbiological testing to accelerate clinical and commercial timelines.
Source: Contract Pharma Breaking News RSS
Neuland, Gland Pharma Expand Sterile API Capacity via Visakhapatnam Partnership
- Gland Pharma will build a dedicated sterile API manufacturing suite at its Visakhapatnam JNPC facility exclusively for Neuland, adding ~1,400 kg annual capacity.
- The partnership combines Neuland's complex API expertise with Gland's aseptic manufacturing capabilities, enabling integrated development-to-commercial supply for customers.
- The suite will operate to cGMP, USFDA, and EU standards, supporting Neuland's growing demand for sterile API products.
Operational Impact
Neuland gains dedicated sterile API capacity at Gland's Visakhapatnam JNPC facility, reducing outsourcing fragmentation and enabling single-partner integrated development-to-commercial supply for sterile API customers.
Source: Web search